Literature DB >> 69411

Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis.

.   

Abstract

The relapse rate up to 5 years after the start of chemotherapy with a 6-month regimen of daily streptomycin, isoniazid, and rifampin has been compared with the rate for a standard 18-month regimen of streptomycin, thiacetazone, and isoniazid for 2 months, followed by thiacetazone and isoniazid for 16 months daily. There were 5 bacteriologic relapses in 145 patients on the 6-month regimen, 1 occurring between 3 and 5 years after admission compared with 3 in 125 patients on the 18-month regimen, 1 occurring between 3 and 5 years.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69411     DOI: 10.1164/arrd.1977.116.1.3

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

1.  High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  Contemp Clin Trials       Date:  2020-01-22       Impact factor: 2.226

Review 2.  Cost effectiveness of antituberculosis interventions.

Authors:  A Castelo; P A Mathiasi; R Iunes; A L Kritski; M Dalcolmo; F Fiuza de Melo; M Drummond
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

3.  Short course chemotherapy for tuberculosis in children.

Authors:  B L Varudkar
Journal:  Indian J Pediatr       Date:  1985 Nov-Dec       Impact factor: 1.967

Review 4.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 5.  Short-course therapy for tuberculosis.

Authors:  M Aquinas
Journal:  Drugs       Date:  1982-08       Impact factor: 9.546

Review 6.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

7.  Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.

Authors:  Chia-Lin Tseng; Olivia Oxlade; Dick Menzies; Anne Aspler; Kevin Schwartzman
Journal:  BMC Public Health       Date:  2011-01-26       Impact factor: 3.295

8.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Authors:  Kevin Pethe; Patricia C Sequeira; Sanjay Agarwalla; Kyu Rhee; Kelli Kuhen; Wai Yee Phong; Viral Patel; David Beer; John R Walker; Jeyaraj Duraiswamy; Jan Jiricek; Thomas H Keller; Arnab Chatterjee; Mai Ping Tan; Manjunatha Ujjini; Srinivasa P S Rao; Luis Camacho; Pablo Bifani; Puiying A Mak; Ida Ma; S Whitney Barnes; Zhong Chen; David Plouffe; Pamela Thayalan; Seow Hwee Ng; Melvin Au; Boon Heng Lee; Bee Huat Tan; Sindhu Ravindran; Mahesh Nanjundappa; Xiuhua Lin; Anne Goh; Suresh B Lakshminarayana; Carolyn Shoen; Michael Cynamon; Barry Kreiswirth; Veronique Dartois; Eric C Peters; Richard Glynne; Sydney Brenner; Thomas Dick
Journal:  Nat Commun       Date:  2010-08-24       Impact factor: 14.919

9.  Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.

Authors:  Vary Jacquet; Willy Morose; Kevin Schwartzman; Olivia Oxlade; Graham Barr; Franque Grimard; Dick Menzies
Journal:  BMC Public Health       Date:  2006-08-15       Impact factor: 3.295

10.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.